ASG Fundamental Analysis - AURORA SPINE CORP

Fundamental Rating

Overall ASG gets a fundamental rating of 3 out of 10. We evaluated ASG against 16 industry peers in the Health Care Equipment & Supplies industry. ASG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ASG does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ASG has reported negative net income.

In the past year ASG had a positive cash flow from operations.

ASG had negative earnings in each of the past 5 years.

The reported operating cash flow has been mixed in the past 5 years: ASG reported negative operating cash flow in multiple years.

1.2 Ratios

Looking at the Return On Assets, with a value of -11.49%, ASG belongs to the top of the industry, outperforming 93.75% of the companies in the same industry.

ASG has a Return On Equity of -35.06%. This is amongst the best in the industry. ASG outperforms 93.75% of its industry peers.

		Industry Rank	Sector Rank
ROA	-11.49%
ROE	-35.06%
ROIC	N/A

ROA(3y)-12.48%

ROA(5y)-12.6%

ROE(3y)-29.77%

ROE(5y)-27.75%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ASG's Gross Margin of 59.74% is amongst the best of the industry. ASG outperforms 81.25% of its industry peers.

In the last couple of years the Gross Margin of ASG has grown nicely.

ASG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	59.74%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y9.72%

GM growth 5Y13.74%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ASG does not have a ROIC to compare to the WACC, probably because it is not profitable.

ASG has more shares outstanding than it did 1 year ago.

ASG has more shares outstanding than it did 5 years ago.

ASG has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.03, we must say that ASG is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of ASG (-0.03) is better than 81.25% of its industry peers.

A Debt/Equity ratio of 0.86 indicates that ASG is somewhat dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.86, ASG is in the better half of the industry, outperforming 68.75% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.86
Debt/FCF	N/A
Altman-Z	-0.03

ROIC/WACCN/A

WACC8.23%

2.3 Liquidity

ASG has a Current Ratio of 1.94. This is a normal value and indicates that ASG is financially healthy and should not expect problems in meeting its short term obligations.

ASG has a Current ratio of 1.94. This is amongst the best in the industry. ASG outperforms 93.75% of its industry peers.

ASG has a Quick Ratio of 1.10. This is a normal value and indicates that ASG is financially healthy and should not expect problems in meeting its short term obligations.

The Quick ratio of ASG (1.10) is better than 87.50% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.94
Quick Ratio	1.1

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ASG have decreased strongly by -105.95% in the last year.

Looking at the last year, ASG shows a small growth in Revenue. The Revenue has grown by 6.76% in the last year.

Measured over the past years, ASG shows a quite strong growth in Revenue. The Revenue has been growing by 9.51% on average per year.

EPS 1Y (TTM)-105.95%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-300%

Revenue 1Y (TTM)6.76%

Revenue growth 3Y18.54%

Revenue growth 5Y9.51%

Sales Q2Q%-7.05%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ASG. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

87.50% of the companies in the same industry are more expensive than ASG, based on the Enterprise Value to EBITDA ratio.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	147.34

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ASG!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

AURORA SPINE CORP

TSX-V:ASG (1/8/2026, 7:00:00 PM)

0.27

+0.01 (+3.85%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)11-19 2025-11-19

Earnings (Next)04-27 2026-04-27

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners25.18%

Ins Owner ChangeN/A

Market Cap20.85M

Revenue(TTM)18.05M

Net Income(TTM)-1.34M

Analysts0

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.84
P/FCF	N/A
P/OCF	27.75
P/B	3.94
P/tB	4.82
EV/EBITDA	147.34

EPS(TTM)-0.02

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0

FCFYN/A

OCF(TTM)0.01

OCFY3.6%

SpS0.32

BVpS0.07

TBVpS0.06

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-11.49%
ROE	-35.06%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	59.74%
FCFM	N/A

ROA(3y)-12.48%

ROA(5y)-12.6%

ROE(3y)-29.77%

ROE(5y)-27.75%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y9.72%

GM growth 5Y13.74%

F-Score4

Asset Turnover1.54

Health

		Industry Rank	Sector Rank
Debt/Equity	0.86
Debt/FCF	N/A
Debt/EBITDA	27.68
Cap/Depr	63.01%
Cap/Sales	3.67%
Interest Coverage	N/A
Cash Conversion	459.16%
Profit Quality	N/A
Current Ratio	1.94
Quick Ratio	1.1
Altman-Z	-0.03

F-Score4

WACC8.23%

ROIC/WACCN/A

Cap/Depr(3y)69.84%

Cap/Depr(5y)82.94%

Cap/Sales(3y)4.27%

Cap/Sales(5y)5.21%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-105.95%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-300%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)6.76%

Revenue growth 3Y18.54%

Revenue growth 5Y9.51%

Sales Q2Q%-7.05%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-103.69%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y85.71%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y307.04%

OCF growth 3YN/A

OCF growth 5Y319.03%

AURORA SPINE CORP / ASG.CA FAQ

What is the ChartMill fundamental rating of AURORA SPINE CORP (ASG.CA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ASG.CA.

Can you provide the valuation status for AURORA SPINE CORP?

ChartMill assigns a valuation rating of 1 / 10 to AURORA SPINE CORP (ASG.CA). This can be considered as Overvalued.

How profitable is AURORA SPINE CORP (ASG.CA) stock?

AURORA SPINE CORP (ASG.CA) has a profitability rating of 3 / 10.

How financially healthy is AURORA SPINE CORP?

The financial health rating of AURORA SPINE CORP (ASG.CA) is 4 / 10.

AURORA SPINE CORP (ASG.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

AURORA SPINE CORP / ASG.CA FAQ

What is the ChartMill fundamental rating of AURORA SPINE CORP (ASG.CA) stock?

Can you provide the valuation status for AURORA SPINE CORP?

How profitable is AURORA SPINE CORP (ASG.CA) stock?

How financially healthy is AURORA SPINE CORP?